Percheron Therapeutics LimitedASX: PER

Completion of HMBD-002 Drug Product Manufacture

· Issued by Percheron Therapeutics Limited via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The drug product will be shipped to Vanderbilt Health for use in clinical trials targeting acute myeloid leukaemia and myelodysplastic syndrome. This milestone is crucial for the upcoming investigator-sponsored study, with trial startup activities expected to begin soon.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement COMPLETION OF HMBD-002 DRUG PRODUCT MANUFACTURE • HMBD-002 has been approved for release and clinical use in accordance with Good Manufacturing Practice (GMP) standards. • HMBD-002 Drug Product to be shipped to Vandebilt Health for use in acute myeloid leukaemia (AML) and...

Percheron Therapeutics Limited on 6ix

Earlier from Percheron Therapeutics

Later from Percheron Therapeutics

All Percheron Therapeutics news releases